Tsukasa Yamamoto

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

Kwang Su Kim, Shinji Watanabe, H. Ebihara, 2022, bioRxiv.

Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity

Tadaki Suzuki, H. Sugiyama, A. Matsunaga, 2022, Journal of Infection and Chemotherapy.

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Shinji Watanabe, H. Ebihara, Y. Kaku, 2022, Med.

Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters

Shinji Watanabe, S. Fukushi, N. Nagata, 2022, bioRxiv.

Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan

Y. Kawaoka, Mutsumi Ito, A. Yasuhara, 2023, One Health.

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants

S. Fukushi, Y. Kirita, Y. Adachi, 2023, Nature communications.

Pet Animals Were Infected with SARS-CoV-2 from Their Owners Who Developed COVID-19: Case Series Study

M. Kuroda, T. Sekizuka, T. Fujimoto, 2023, Viruses.